Piramal Pharma to Acquire Balance 26% Stake in Subsidiary Yapan Bio
Piramal Pharma Ltd 路 Others (Uncategorized) 路 18 Nov 2026, 10:31 pm
Piramal Pharma to Acquire Balance 26% Stake in Subsidiary Yapan Bio Piramal Pharma's Administrative Committee approved exercising its call option to acquire the remaining 26% equity stake in subsidiary Yapan Bio Private Limited from existing shareholders. Following completion of the transaction, Piramal Pharma's shareholding in Yapan will increase from 74% to 100%, making it a wholly owned subsidiary. Yapan operates as a CDMO specializing in process development, characterization, and Phase I/II GMP manufacturing for vaccines and biologics. Final terms, including acquisition consideration and effective transfer date, remain subject to finalization and definitive documentation.
Original exchange filing (PDF)
More announcements from Piramal Pharma Ltd
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund 路 31 Oct 2026
- Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI LODR Regulations, 2015 路 30 Oct 2026
- Please find enclosed details of Earning call Transcript held on 28th October 2026. 路 30 Oct 2026
- Please find enclosed intimation of audio recordings of the conference call held today 28th October, 2026. 路 28 Oct 2026
- Please find enclosed Investor presentation for quarter ended 30 September, 2026 路 28 Oct 2026
- Please find enclosed Press release for quarter ended 30 September, 2026 路 28 Oct 2026
- Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 28 Oct 2026
- Please find enclosed unaudited financial results for Q2 FY 27 路 28 Oct 2026
